Skip to content

The Effect of Modafinil on Affective and Cognitive Processing

The Effect of Modafinil on Neural Processing During the Interference and Feedback Based Learning Task

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03426202
Enrollment
60
Registered
2018-02-08
Start date
2018-01-01
Completion date
2020-07-01
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

modafinil, emotion, cognitive processing

Brief summary

The study aims to examine whether a single dose of modafinil (200mg, p.o.) can affect feedback-based learning and interference processing in healthy male subjects.

Detailed description

Based on previous animal and human research suggesting a catecholamine-mediated, potentially pro-cognitive, mechanism of action of modafinil, the present study seeks to explore effects of modafinil on feedback-based learning and interference processing in healthy subjects. To this end, the present randomized double-blind, between-subject, placebo-controlled pharmaco-fMRI experiment plans to determine the behavioral and neural effects of a single dose of p.o.modafinil (200mg) versus placebo on validated feedback-based learning and emotional/non-emotional cognitive conflict paradigms. To control for potential effects of pre-medication personality traits as well as effects of modafinil on subjective task performance, subjects will be administered pre-treatment assessing relevant personality traits and post-treatment assessments of meta-cognitive confidence estimation.

Interventions

DRUGModafinil Oral Tablet

modafinil 200mg

DRUGPlacebo Oral Tablet

placebo 200mg

Sponsors

University of Electronic Science and Technology of China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects without past or current psychiatric or neurological disorders * Non-smokers * Right-handedness

Exclusion criteria

* Medical or psychiatric illness * Allergy against medications or general strong allergies * Sleep disorders * High blood pressure, general cardio-vascular alterations * History of head injury * Visual or motor impairments

Design outcomes

Primary

MeasureTime frameDescription
Neural processing during the interference processing4h after treatmentfMRI BOLD indices of neural processing in interference related brain regions will be compared between the treatment and placebo group.
Neural processing during feedback based learning4h after treatmentfMRI BOLD indices of neural processing learning related brain regions will be compared between the treatment and placebo group.

Secondary

MeasureTime frameDescription
Behavioral interference performance - Response Time4h after treatmentBehavioral performance of interference performance for congruent and incongruent stimuli (picture vs word) will be compared between the treatment and placebo group.
Behavioral interference performance - Accuracy4h after treatmentBehavioral performance of interference in terms of accuracy for congruent and incongruent trials (picture vs word) will be compared between the treatment and placebo group.
Behavioral learning performance - Reaction time4h after treatmentLearning performance in terms of reaction times will be compared between the treatment and placebo group.
Behavioral learning performance - Accuracy4h after treatmentLearning performance in terms of accuracy (learning curve, trials to reach plateau) will be compared between the treatment and placebo group.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026